Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194
Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.
[ Get More Details ]
Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for… [ Get More Details ]
Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence… [ Get More Details ]